/Investor DB

Anterra Capital — 2016 Investments

1 investments dated 2016 · listed companies and verified rows first · show all

Caribou Biosciencescariboubio.comin𝕏NASDAQ: CRBUSeries B · May 2016 · $30M

Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.

BiotechMedical DevicesBerkeley, US

Jennifer Doudna(Founder)Rachel Haurwitz(Founder)inMartin Jinek(Founder)Andrew May(Executive Officer)James Berger(Founder)

BoardJenny Rooke(Director)in

Co-investorsAliment CapitalAvego BioScience CapitalF-Prime CapitalIA Seed VenturesLifeSci Venture PartnersMission Bay Capital+3 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.